Identification of stem-like cells in non-small cell lung cancer cells with specific peptides.
Recent studies indicate that tumor maintenance, metastasis and drug-resistance are mainly conducted by a small subset of cancer cells which are termed cancer stem cells (CSCs) or cancer stem-like cells (CSLCs). Successful identification of CSCs/CSLCs might lead to discovery of the novel and effective therapeutic targets for cancers. In our study, lung CSCs/CSLCs were enriched by sphere-forming assay. Screening and selection of specific binding peptides for lung CSCs/CSLCs were performed with bacterial surface display method. Selected peptide named HCBP-1 exhibited highest specific binding capability as examined by flow cytometry and fluorescence microscopy. Drug-resistant lung CSCs/CSLCs might be characterized with HCBP-1 peptide and several microRNAs related to the stem-like properties were discriminatively expressed in HCBP-1+ subpopulation. Moreover, at least two distinct subpopulations in H460 tumor sphere cells could be distinguished by HCBP-1 peptide. Thus, a new method was established to identify lung CSCs/CSLCs, which provided robust approaches for the research of CSCs/CSLCs.
Key Laboratory for Nano-Bio Interface Research, Suzhou Key Laboratory for Nanotheranostics, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China; Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Anxin
A
Wang
Key Laboratory for Nano-Bio Interface Research, Suzhou Key Laboratory for Nanotheranostics, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China; Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Lisha
L
Chen
Key Laboratory for Nano-Bio Interface Research, Suzhou Key Laboratory for Nanotheranostics, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China; Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Kefeng
K
Pu
Key Laboratory for Nano-Bio Interface Research, Suzhou Key Laboratory for Nanotheranostics, Division of Nanobiomedicine, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China. Electronic address: ymzhu2008@sinano.ac.cn.
Yimin
Y
Zhu
D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002945:Cisplatin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004926:Escherichia coli; D005434:Flow Cytometry; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D019151:Peptide Library; D010456:Peptides, Cyclic / Q000096:biosynthesis / Q000737:chemistry*; D011485:Protein Binding; D018874:Spheroids, Cellular / Q000378:metabolism; D013194:Staining and Labeling; D059467:Transcriptome
D000970:Antineoplastic Agents; D035683:MicroRNAs; D019151:Peptide Library; D010456:Peptides, Cyclic; D002945:Cisplatin
Bacterial surface display; Cancer stem-like cells; MicroRNA; Peptide; Tumor spheres